Department of Paediatric Oncology/Haematology, Kinderkrankenhaus Amsterdamer Straße, Cologne, Germany.
Department of Paediatric Oncology/Haematology/BMT, Charité - Universitätsmedizin Berlin, Berlin, Germany.
Br J Haematol. 2018 Nov;183(4):648-660. doi: 10.1111/bjh.15600. Epub 2018 Oct 18.
Sickle Cell Disease (SCD) is an increasing global health problem and presents significant challenges to European health care systems. Newborn screening (NBS) for SCD enables early initiation of preventive measures and has contributed to a reduction in childhood mortality from SCD. Policies and methodologies for NBS vary in different countries, and this might have consequences for the quality of care and clinical outcomes for SCD across Europe. A two-day Pan-European consensus conference was held in Berlin in April 2017 in order to appraise the current status of NBS for SCD and to develop consensus-based statements on indications and methodology for NBS for SCD in Europe. More than 50 SCD experts from 13 European countries participated in the conference. This paper aims to summarise the discussions and present consensus recommendations which can be used to support the development of NBS programmes in European countries where they do not yet exist, and to review existing programmes.
镰状细胞病(SCD)是一个日益严重的全球健康问题,给欧洲医疗保健系统带来了重大挑战。新生儿镰状细胞病筛查(NBS)可以实现早期预防措施的启动,并有助于降低儿童因 SCD 导致的死亡率。不同国家的 NBS 政策和方法各不相同,这可能会对整个欧洲 SCD 的护理质量和临床结果产生影响。为了评估 SCD 的 NBS 现状,并制定有关 SCD 的 NBS 适应症和方法的基于共识的声明,2017 年 4 月在柏林举行了为期两天的泛欧共识会议。来自 13 个欧洲国家的 50 多名 SCD 专家参加了会议。本文旨在总结讨论并提出共识建议,以支持尚未开展 NBS 项目的欧洲国家制定 NBS 项目,并审查现有项目。